ARCHIVES

ODAC Unanimously Rejects Melblez, Citing Lower Survival

This article is from The Cancer Letter archive.

Vol. 39 No. 20 | May 17, 2013

Download PDF Visit The Full Archive

Related Articles

Cancer Letter, PR Firm Settle Out Of Court On Copyright Violation

November 27, 1987

Clinical Trials Approved By NCI Last Month Are Listed

August 29, 2003

NCI Plans Preclinical Studies Of Endoxifen, A Tamoxifen Metabolite.

August 7, 2009

DCBDC Board OK’s Concepts For New Small Grant Programs

March 23, 1990

ASRO President Tells Colleagues To Take Charge

October 26, 1990

Royston Retires At Kimmel; Cancer Care Gives Awards.

June 22, 2001